A case of chronic tophi gout in morbidly obese patient after laparoscopic adjustable gastric banding

Currently, increasing attention is being paid to studying the metabolic activity of adipose tissue, a source of biologically active mediators involved in vascular remodeling, immunological and inflammatory reactions. Today obesity is considered not only as independent risk factor of development of chronic noninfectious diseases (such as arterial hypertension, diabetes mellitus types 2, pathology of a cardiovascular system, malignant neoplasms), but also as a significant predictor of metabolic disorders (dyslipidemia, insulin resistance, hyperuricemia), contributes to the early formation of metabolic syndrome and goat. Despite such an obvious problem, the current state of conservative therapy for overweight and obesity remains unsatisfactory. Most of patients, even after successful treatment, have a recurrence of the disease with the restoration of the initial anthropometric indicators or even an increase in body weight. In this regard, currently more widely used surgical methods of correction of obesity. However along with the expected positive effects of treatment bariatric surgery may be accompanied by the development of a number of specific surgical complications and impaired energy metabolism with aggravation of the existing polymorbid pathology. This clinical case demonstrates the association of obesity with the development of metabolic disorders, illustrates the development of severe tophaceous gout in a patient during 2 years after laparoscopic gastric banding. It shows the possible reasons for its debut and reflects the dynamics of the patient’s condition, as well as the nature and characteristics of the course of the joint syndrome in the postoperative period.

1. Лазнам С.С., Берштейн Л.Л., Гришкин Ю.Н. Значение оценки факторов сердечно-сосудистого риска в прогнозировании ишемической болезни сердца. // Вестник Российской военно-медицинской академии. — 2011. — №4. — С. 185-194. [Laznam SS, Berstein LL, Grishkin YN. The role of risk factors assesement in predicting coronary heart disease. Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2011;(4):185-194. (In Russ).]

2. Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity. 2008;16(6):1161-1177. DOI:10.1038/oby.2008.231

3. Choi HK, Ford ES, Li CY, Curhan G. Revalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-115. DOI:10.1002/art.22466

4. Насонова В.А., Елисеев М.С., Барскова В.Г. Влияние возраста на частоту и выраженность признаков метаболического синдрома у больных подагрой. // Современная ревматология. — 2007. — №1. — С.31–36. [Nasonova VA, Eliseev MS, Barskova VG. Impact of age on the frequency and magnitude of the signs of metabolic syndrome in patients with gout. Modern Rheumatology Journal. 2007;1(1):31-36. (In Russ).] DOI:10.14412/1996-7012-2007-436

5. Савельева Л.В. Современная концепция лечения ожирения. // Ожирение и метаболизм. — 2011. — Т. 8. — №1. — С. 51-56. [Savel’eva LV. Sovremennaya kontseptsiya lecheniya ozhireniya. Obesity and metabolism. 2011;8(1):51-56. (In Russ).] DOI:10.14341/2071-8713-5191

6. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27(12):1437-1446. DOI:10.1038/sj.ijo.0802475

7. Karlsson J, Taft C, Rydén A, et al. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. Int J Obes (Lond). 2007;31(8);1248-1261. DOI:10.1038/sj.ijo.0803573

8. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741-752. DOI:10.1056/NEJMoa066254

9. Dalbeth N, Chen P, White M, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis. 2014;73(5):797-802. DOI:10.1136/annrheumdis-2013-203970

10. Фишман М.Б., Седов В.М., Ван Я. Регулируемое бандажирование желудка. Иллюзии и реальность. // Вестник хирургии имени И.И. Грекова. — 2016. — Т. 175. — №2. — С. 25-29. [Fishman MB, Sedov VM, Yan V. Laparoscopic adjustable gastric banding. Illusions and reality. Vestn Khir Im I I Grek. 2016;175(2):25-29. (In Russ).] DOI:10.24884/0042-4625-2016-175-2-25-29

11. Buchwald H, Danette MO. Metabolic/bariatric surgery worldwide 2011. Obes Surg. 2013;23(4):427-436. DOI:10.1007/s11695-012-0864-0

12. Отт А.В., Чумакова Г.А., Веселовская Н.Г. Эпикардиальное ожирение как один из основных критериев метаболически тучного фенотипа ожирения // Сибирское медицинское обозрение. — 2017. — №4. — С.44–53. [Ott AV, Chumakova GA, Veselovskaya NG. Epicardial obesity as one of the main criteria for the metabolic obese phenotype of obesity. Siberian Medical Review. 2017;(4):44-53. (In Russ).] DOI:10.20333/2500136-2017-4-44-53

13. Бабенко А.Ю., Неймарк А.Е., Анисимова К.А., Гринева Е.Н. Эффекты бариатрических операций на уровень гормонов, регулирующих массу тела. В чем основа успеха? // Ожирение и метаболизм. — 2014. — Т. 11. — №4. — С. 3-11. [Babenko AY, Neymark AE, Anisimova KA, Grineva EN. Effects of bariatric surgery on the level of hormones that regulate body weight. What is the basis of success? Obesity and metabolism. 2014;11(4):3-11. (In Russ).] DOI:10.14341/omet201443-11

14. Морбидное ожирение. / Под ред. Дедова И.И. — М.: Медицинское информационное агентство, 2014. [Dedov II, editor. Morbidnoe ozhirenie. Moscow: Meditsinskoe informatsionnoe agentstvo; 2014. (In Russ).]

15. Maglio C, Peltonen M, Neovius M, et al. Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial. Ann Rheum Dis. 2017;76(4):688-693. DOI:10.1136/annrheumdis-2016-209958

16. Romero-Talamás H, Daigle CR, Aminian A, et al. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis. 2014;10(6):1161-1165. DOI:10.1016/j.soard.2014.02.025

17. Yeo C, Kaushal S, Lim B, et al. Impact of bariatric surgery on serum uric acid levels and the incidence of gout-A meta-analysis. Obes Rev. 2019;20(12):1759-1770. DOI:10.1111/obr.12940

18. Kang EH, Lee EY, Lee YJ, et al. Clinical features and risk factors of postsurgical gout. Ann Rheum Dis. 2008;67(9):1271-1275. DOI:10.1136/ard.2007.078683

19. Antozzi P, Soto F, Arias F, et al. Development of Acute Gouty Attack in the Morbidly Obese Population after Bariatric Surgery. Obes Surg. 2005;15(3):405-407. DOI:10.1381/0960892053576802

20. Raziel A. Gout, obesity and bariatric surgery. Adv Obes Weight Manag Control. 2018;8(4):224-229. DOI:10.15406/aowmc.2018.08.00248

21. Zhang Y, Chaisson CE, McAlindon T, et al. The online case-crossover study is a novel approach to study triggers for recurrent disease flares. J Clin Epidemiol. 2007;60(1):50-55. DOI:10.1016/j.jclinepi.2006.04.006

22. Nguyen UDT, Zhang Y, Louie-Gao Q, et al. The Obesity Paradox in Recurrent Attacks of Gout in Observational Studies: Clarification and Remedy. Arthritis Care Res (Hoboken). 2017;69(4):561-566. DOI:10.1002/acr.22954

23. Дедов И.И., Мельниченко Г.А., Бутрова С.А. Жировая ткань как эндокринный орган. // Ожирение и метаболизм. — 2006. — Т. 3. — №1. — С. 6-13. [Dedov II, Mel’nichenko GA, Butrova SA. Zhirovaya tkan’ kak ehndokrinnyy organ. Obesity and metabolism. 2006;3(1):6-13. (In Russ).] DOI:10.14341/2071-8713-4937

24. Денисов И.С., Елисеев М.С., Барскова В.Г. Исходы подагры. Обзор литературы. Часть II. Коморбидные заболевания, риск развития сердечно-сосудистых катастроф и смерти при подагре. // Проблемы практической ревматологии. — 2013. — Т. 51. — №6. — С. 703-710. [Denisov IS, Eliseev MS, Barskova VG. Gout outcomes. Literature review. Part II. Comorbid diseases, risk of developing cardiovascular catastrophes and death in gout patients. Rheumatology Science and Practice. 2013;51(6):703-710. (In Russ).] doi: http://doi.org/10.14412/1995-4484-2013-703-10

25. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364-376. DOI:10.1038/nrendo.2014.44

26. Roddy E, Choi HK. Epidemiology of gout. Rheum Dis Clin North Am. 2014;40(2):155-175. DOI:10.1016/j.rdc.2014.01.001

27. Маркелова Е.И., Елисеев М.С., Барскова В.Г. Артериальная гипертензия у больных подагрой: основы патогенеза, клиническое значение, диагностика. // Современная ревматология. — 2012. — Т. 6. — №4. — С. 23-30. [Markelova EI, Eliseyev MS, Barskova VG. Arterial hypertension in gout patients: Pathogenesis bases, clinical value, diagnosis. Sovremennaia revmatologiia. 2012;6(4):23-30. (In Russ).]

28. Maciejewski ML, Arterburn DE, Van Scoyoc L, et al. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016;151(11):1046-1055. doi: https://doi.rog/10.1001/jamasurg.2016.2317

29. Шулькина С.Г. Метаболические, гормональные и генетические факторы в формировании фенотипа ожирения, их значение в развитии почечной дисфункции и эффективность терапевтического воздействия: Дис. … д-ра мед. наук. — Пермь; 2018. [Shul’kina SG. Metabolicheskie, gormonal’nye i geneticheskie faktory v formirovanii fenotipa ozhireniya, ikh znachenie v razvitii pochechnoy disfunktsii i effektivnost’ terapevticheskogo vozdeystviya. [dissertation] Perm’; 2018. (In Russ).]